HK Stock Market Move | ZHAOKE OPHTH-B(06622) rose nearly 4%, core product NVK002 simplified new drug application recently received acceptance.

ZHAOKE OPHTH-B(06622) rose by nearly 4%, reaching 3.88% at the time of publication, at 1.34 Hong Kong dollars, with a turnover of 2.86 million Hong Kong dollars. On the news front, ZHAOKE OPHTH-B recently announced that the National Medical Products Administration has officially accepted the company's application for a new drug for NVK002 (0.01% low-dose atropine). NVK002 is one of the company's most promising core drugs, used to control the progression of myopia in children and adolescents. The application for the new drug for NVK002 is based on Phase III clinical trials conducted by ZHAOKE OPHTH-B in China. It is worth mentioning that currently, the only atropine sulfate eye drops available in China are the Xingqi Meio brand from Shenyang Xingqi Pharmaceutical, which was approved on March 11, 2024.